Advances in cardiovascular safety of SGLT-2 inhibitors and GLP-1 receptor agonists

VernacularTitle:SGLT-2抑制剂和GLP-1受体激动剂的心血管安全性研究进展
Author: Yanlan LAI ^{1
,

2} ; Aiwen HUANG ³ ; Lili ZHANG ³ ; Xiaolan LIAO ^{1
,

2} ; Lijun ZHAO ^{1
,

2} ; Hongtao SONG ³
Author Information

1. Department of Pharmacy, No. 900 Hospital of Joint Logistics Support Force of the PLA, Fuzhou 350025, China
2. Department of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.
3. Department of Pharmacy, No. 900 Hospital of Joint Logistics Support Force of the PLA, Fuzhou 350025, China.
Keywords: SGLT-2 inhibitors; GLP-1 receptor agonists; type 2 diabetes; cardiovascular safety
From: Journal of Pharmaceutical Practice 2020;38(6):496-500
CountryChina
Language:Chinese
Abstract: Type 2 diabetes is a high risk factor for atherosclerotic cardiovascular disease. Studies have found that SGLT-2 inhibitor and GLP-1 receptor agonists have cardiovascular protective effects in patients with type 2 diabetes and cardiovascular disease. Therefore, from the aspects of cardiovascular safety test and its Meta-analysis and net-like Meta-analysis, the research progress of cardiovascular safety of SGLT-2 inhibitors and GLP-1 receptor agonists is summarized.